# ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

> **NCT07089641** · PHASE1 · RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 10 (estimated)

## Conditions studied

- IDH Wildtype Glioblastoma
- Recurrent Astrocytoma
- IDH Wildtype Recurrent Glioblastoma
- Resectable Astrocytoma
- Resectable Glioblastoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Echocardiography Test
- **DRUG:** EGFR Inhibitor ERAS-801
- **OTHER:** Fludeoxyglucose F-18
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Surgical Procedure

## Key facts

- **NCT ID:** NCT07089641
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-28
- **Primary completion:** 2027-07-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- National Institutes of Health (NIH)
- United States Department of Defense

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07089641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07089641, "ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT07089641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*